Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly.
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical ...
Zydus introduces biosimilar denosumab 120 mg SC – protecting bone health in cancer patients: Our Bureau, Mumbai Wednesday, December 10, 2025, 13:30 Hrs [IST] Zydus Lifesciences ...
In May 2025, former President Joe Biden's health took a serious turn when his medical team revealed a diagnosis of aggressive ...
In November 2025, Rana McKay, MD initiated a phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC). DelveInsight's Bone ...
Capital Market on MSN
Zydus Lifesciences gains after launching denosumab biosimilar
Denosumab is a monoclonal antibody with several indications related to bone health, primarily used in the treatment of ...
JANX007 shows significant PSA reductions and favorable rPFS in mCRPC patients, with a manageable safety profile. The trial identifies 6 mg and 9 mg as optimal doses, balancing safety and efficacy.
Combined androgen blockade shows significant survival benefits over single-agent ADT in high-risk prostate cancer, as demonstrated by the PRESTO, EMBARK, and ENZARAD trials. The PRESTO trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results